

- Pneumonia (*Continued*)
 hospital-acquired, 703t, 707-708
 idiopathic chronic eosinophilic, 695
 in immunocompromised host, 703t, 711, 711t
 lobar, 704b-705b, 704f
 lung abscess, 703t, 708-709, 708b-709b
 necrotizing, 703t
 usual interstitial, 686f
- Pneumonic plague, 370b
- Podocytes, 900, 901f, 903b
- POEMS syndrome, 1234
- Poison, definition of, 406
- Polarity, loss of, in neoplasia, 270
- Poliomyelitis, 1277, 1277b
- Poliovirus infection, 356
- Pollution, environmental, 407-410
 air, 407-410
 metals, 410-413
- Polonium 214 and 218, as carcinogens, 432
- Polyarteritis nodosa, 207t, 231, 509-510, 509b, 510f
 cerebral infarction due to, 1266
- Polychlorinated biphenyls (PCBs),
 occupational health risks, 414
- Polycyclic hydrocarbons, occupational health risks, 413
- Polycystic kidney disease
 autosomal dominant (adult), 945-947, 945f, 946f, 947f, 945t, 947b
 autosomal recessive (childhood), 945f, 945t, 947-948, 948b
- Polycystic ovarian syndrome (PCOS), 1022
- Polycythemia, 656
 absolute, 656
 pathophysiologic classification of, 656t
 relative, 656
- Polycythemia vera (PCV), 618-619, 619f, 656
 morphology of, 618b-619b
- Polydactyly, 453f
- Polyethylene, 1214
- Polyglucosan bodies, 1253
- Polyglutamine diseases, 1299
- Polykaryons, 353
- Polymerase chain reaction (PCR) test, for infectious agents, 354
- Polymicrogyria, 1257
- Polymorphic markers, 178-180, 179f
- Polymorphisms
 and genome-wide analyses, 179-180
 single nucleotide, 178
- Polymyositis, 1239, 1239b
- Polyneuropathies, 1230
- Polyol pathways, intracellular hyperglycemia and disturbances in, 1116
- Polyomavirus nephropathy, 933, 933f
- Polyp(s), 266
 colonic, 267f
 fibroepithelial, of ureters, 960
 stomach, 769-777
 fundic gland, 770, 770b
 inflammatory and hyperplastic, 770, 770b, 770f
- Polypoid cystitis, 963
- Polyradiculoneuropathies, 1230
- Pompe disease, 158f, 1244-1245
- Porphyria, 1171-1172, 1173f
- Port wine stain, 516
- Portal hypertension, 826-827
 consequences of, 829f
 location/causes of, 829t
 in right-sided heart failure, 530
- Portal system, in right-sided heart failure, 530
- Portal vein obstruction/thrombosis, 862-863
- Portopulmonary hypertension, 830
- Portosystemic shunts, 830
- Posterior fossa anomalies, 1258
- Posterior subcapsular cataract, 1327
- Posterior synechiae, 1329
- Postinfectious glomerulonephritis, 912
- Postmenopausal osteoporosis, 1188-1189, 1188f
- Postmortem clots, 125
- Postpolio syndrome, 1277
- Postrenal azotemia, 898
- Poststreptococcal glomerulonephritis, 207t, 909-912
- Posttranscriptional silencing, 4-5
- Posttranslational modifications, 149
- Posttraumatic hydrocephalus, 1263
- Potocytosis, 9
- Pott, Percival, 321-322
- Pott disease, 374b-376b, 1196
- Potter sequence, 452-453, 453f, 454f
- Poverty, and malnutrition, 432
- Prader-Willi syndrome, 172-174, 173f, 446
- Pre-B cells, 240
- Preconditioning, of myocardium, 547
- Precursor B-cell neoplasms, 590-593
- Precursor lesions, 279
- Preeclampsia, 457, 866
 morphology of, 866b
- Pregnancy
 and breast cancer, 1053
 breast during, 1043-1044
 hepatic disease associated with, 865-867
 toxemia of, 457
- Pregnancy disorder(s), 1035-1036
 choriocarcinoma, 1041, 1041b, 1041f
 ectopic pregnancy, 1036
 gestational trophoblastic disease, 1039-1042
 hydatidiform mole, 1039-1041, 1040b, 1040f
 of placental implantation, 1037
 placental infections, 1037, 1037f
 placental site trophoblastic tumor, 1041-1042
 preeclampsia and eclampsia, 1037-1039, 1038f, 1039f
 spontaneous abortion, 1035-1036
 twin placentas, 1036-1037, 1037f
- Pregnancy luteoma, 1034
- Prematurity, 456-459
 necrotizing enterocolitis with, 459, 460f
 neonatal respiratory distress syndrome with, 457-459, 458f
 retinopathy of, 459
- Premutations, in fragile-X syndrome, 170
- Prerenal azotemia, 898
 in left-sided heart failure, 529
- Pressure atrophy, 37
- Pressure-overload hypertrophy, 527
- Preterm, 456
- Preterm premature rupture of placental membranes (PPROM), 456
- Pretibial myxedema, 1089
- Primary acinar cell injury, 885-886, 885f
- Primary acute adrenocortical insufficiency, 1129
- Primary adrenocortical neoplasms, 1124b
- Primary angle-closure glaucoma, 1328f, 1329
- Primary autoimmune adrenalitis, 1131b, 1131f
- Primary biliary cirrhosis (PBC), 829t, 858-859, 859f, 860b-861b
 main features of, 858t
 morphology of, 858b-859b
- Primary ciliary dyskinesia, 683
- Primary CNS lymphoma, 1313-1314, 1314b
- Primary effusion lymphoma, 254, 596
- Primary gout, 1215
- Primary hepatolithiasis, 855-856, 856f, 860b-861b
 morphology of, 856b
- Primary hyperplasia, in hyperparathyroidism, 1102b-1103b
- Primary immune deficiency diseases, 239f, 243b
- Primary/immunocyte-associated amyloidosis, 599
- Primary immunodeficiencies, 237
- Primary malnutrition, 432
- Primary myelofibrosis, 620-621, 621f
 morphology of, 620b-621b
- Primary open-angle glaucoma, 1328
- Primary sclerosing cholangitis, 859-861, 860b-861b, 860f
 main features of, 858t
 morphology of, 860b
- Primary spongiosa, 1181f
- Prinzmetal variant angina, 540
- Prion diseases, 1281-1283, 1282f, 1283f
- Prion protein (PrP), 1281
- Pro-apoptotic *Bcl* family, 55
- Procaspase 8, in apoptosis, 302
- Progenitor cells, liver regeneration from, 102
- Progesterone receptors, in breast carcinoma, 1068
- Programmed cell death, 52
 biochemical pathways of, 302-303
 evasion of, 301-303
- Progressive bulbar palsy, in amyotrophic lateral sclerosis, 1300
- Progressive multifocal leukoencephalopathy (PML), 1278-1279, 1278b-1279b, 1279f
- Progressive muscular atrophy, in amyotrophic lateral sclerosis, 1300
- Progressive supranuclear palsy (PSP), 1296, 1296b
- Pro-growth signaling pathways, 1148-1149
- Proinflammatory cytokines, 435
- Pro-inflammatory effects, in hemostasis, 120
- Prolactin, 1078b
- Prolactinomas, 1078f
- Prolactin-secreting lactotroph adenomas, 1078
- Proliferative breast disease
 with atypia, 1050-1051, 1050b, 1051t
 without atypia, 1048-1050, 1049b, 1051t
- Proliferative diabetic retinopathy, 1336
- Proliferative vitreoretinopathy, 1333
- Promoters, 324
- Promotion, of chemical carcinogenesis, 322, 322f, 324
- Pro-opiomelanocortin (POMC), 330, 1131
- Propagation, of thrombi, 125
- Proptosis, 1320-1321
- Propylthiouracil, 1083
- Prostacyclin (PGI₂)
 in hemostasis, 121
 in inflammation, 85
- Prostaglandins, in inflammation, 83-85
 pharmacologic inhibitors of, 85-86
- Prostaglandin D₂, 680
 in immediate hypersensitivity, 203